[{"Physician_Profile_ID": "944296", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Alexion Pharmaceuticals, Inc.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "CT", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000005462", "Total_Amount_of_Payment_USDollars": "1819.00", "Date_of_Payment": "07/17/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "215886196", "Name_of_Associated_Covered_Drug_or_Biological1": "SOLIRIS", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Safety ond Efficacy of Eculizumab in Refractory Generalized Myashenia Gravis", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "944296", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Alexion Pharmaceuticals, Inc.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "CT", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000005462", "Total_Amount_of_Payment_USDollars": "1720.00", "Date_of_Payment": "09/29/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "215886202", "Name_of_Associated_Covered_Drug_or_Biological1": "SOLIRIS", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Safety ond Efficacy of Eculizumab in Refractory Generalized Myashenia Gravis", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "944296", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Alexion Pharmaceuticals, Inc.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "CT", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000005462", "Total_Amount_of_Payment_USDollars": "1690.00", "Date_of_Payment": "09/29/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "215886204", "Name_of_Associated_Covered_Drug_or_Biological1": "SOLIRIS", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Safety ond Efficacy of Eculizumab in Refractory Generalized Myashenia Gravis", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "944296", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Alexion Pharmaceuticals, Inc.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "CT", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000005462", "Total_Amount_of_Payment_USDollars": "1420.00", "Date_of_Payment": "09/29/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "215886206", "Name_of_Associated_Covered_Drug_or_Biological1": "SOLIRIS", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Safety ond Efficacy of Eculizumab in Refractory Generalized Myashenia Gravis", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "944296", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Alexion Pharmaceuticals, Inc.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "CT", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000005462", "Total_Amount_of_Payment_USDollars": "1323.00", "Date_of_Payment": "09/29/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "215886208", "Name_of_Associated_Covered_Drug_or_Biological1": "SOLIRIS", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Safety ond Efficacy of Eculizumab in Refractory Generalized Myashenia Gravis", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "944296", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Alexion Pharmaceuticals, Inc.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "CT", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000005462", "Total_Amount_of_Payment_USDollars": "1323.00", "Date_of_Payment": "09/29/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "215886374", "Name_of_Associated_Covered_Drug_or_Biological1": "SOLIRIS", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Safety ond Efficacy of Eculizumab in Refractory Generalized Myashenia Gravis", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "944296", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Alexion Pharmaceuticals, Inc.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "CT", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000005462", "Total_Amount_of_Payment_USDollars": "1100.00", "Date_of_Payment": "12/23/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "215886414", "Name_of_Associated_Covered_Drug_or_Biological1": "SOLIRIS", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Safety ond Efficacy of Eculizumab in Refractory Generalized Myashenia Gravis", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "944296", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Alexion Pharmaceuticals, Inc.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "CT", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000005462", "Total_Amount_of_Payment_USDollars": "998.00", "Date_of_Payment": "09/29/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "215886210", "Name_of_Associated_Covered_Drug_or_Biological1": "SOLIRIS", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Safety ond Efficacy of Eculizumab in Refractory Generalized Myashenia Gravis", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "944296", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Alexion Pharmaceuticals, Inc.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "CT", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000005462", "Total_Amount_of_Payment_USDollars": "938.60", "Date_of_Payment": "07/17/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "215886198", "Name_of_Associated_Covered_Drug_or_Biological1": "SOLIRIS", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Safety ond Efficacy of Eculizumab in Refractory Generalized Myashenia Gravis", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "944296", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Alexion Pharmaceuticals, Inc.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "CT", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000005462", "Total_Amount_of_Payment_USDollars": "164.00", "Date_of_Payment": "07/17/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "215886200", "Name_of_Associated_Covered_Drug_or_Biological1": "SOLIRIS", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Safety ond Efficacy of Eculizumab in Refractory Generalized Myashenia Gravis", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "944296", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Alexion Pharmaceuticals, Inc.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "CT", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000005462", "Total_Amount_of_Payment_USDollars": "101.60", "Date_of_Payment": "09/29/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "215886212", "Name_of_Associated_Covered_Drug_or_Biological1": "SOLIRIS", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Safety ond Efficacy of Eculizumab in Refractory Generalized Myashenia Gravis", "Research_Information_Link": "", "Context_of_Research": ""}]